The most frequently occurring mutations in the EGFR gene (in-frame deletion in exon 19 at codons 746–750 or a single-base substitution L858R in exon 21) predict an improved clinical response to first-line oral EGFR-TKIs compared with standard platinum-based chemotherapy in patients with advanced non-small-cell lung carcinoma (NSCLC) (4, 8). Here, EGFR is linked to non-small cell lung carcinoma.